Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Swiss ask French to stay neutral

This article was originally published in The Tan Sheet

Executive Summary

Novartis "takes note of the invitation by the Aventis Supervisory Board to enter into negotiations regarding a potential transaction," firm says in an April 2 statement. The invitation was one of two conditions outlined by the Swiss firm to be met before entering into merger talks (1"The Tan Sheet" March 29, 2004, p. 5). The second condition was for the French government to "assume a neutral position." Novartis says it expects the Aventis board to "clarify with the French Government the importance of such a transaction for the shareholders of Aventis as well as its benefits for employment and for research and development"...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096672

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel